Showing 6031-6040 of 9511 results for "".
- Alma Lasers' Accent Celebrates 10 Years with a New Campaignhttps://practicaldermatology.com/news/alma-lasers-accent-celebrates-10-years-with-a-new-campaign/2458294/Accent Prime is celebrating a 10 year anniversary with a newly launched campaign. Alma Lasers released the first generation of the Accent branded platform in 2007, with the FDA approval, and technologically enhanced it throughout the pas
- Study Finds Increased Incidence of SCC Among Patients Treated with Biologics for Psoriasishttps://practicaldermatology.com/news/study-find-increased-incidence-of-scc-among-patients-treated-with-biologics-for-psoriasis/2458296/A recent study published in the Journal of the American Academy of Dermatology sought to estimate the overall malignancy rate (excluding non-melanoma skin cancere [NMSC]) and NMSC rate among 5,889 patients with systemically
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only
- FDA OKs Coolsculpting for Upper Arm Fat Reductionhttps://practicaldermatology.com/news/fda-oks-coolsculpting-for-upper-arm-fat-reduction/2458300/ZELTIQ® Aesthetics, Inc.’s CoolSculpting is now US Food and Drug Administration (FDA)-cleared for fat reduction in the upper arms.
- Valeant Dermatology to Award $10,000 Scholarships for Undergraduate and Graduate Degreeshttps://practicaldermatology.com/news/valeant-dermatology-to-award-10000-scholarships-for-undergraduate-and-graduate-degrees/2458302/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, will award nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program. The scholarships will be awarded to students who will be attending undergraduate or graduate education progr
- Teamwork: Solésence and Colorescience Announce Skin Care Collaborationhttps://practicaldermatology.com/news/teamwork-solsence-and-colorescience-announce-skin-care-collaboration/2458303/Solésence is teaming up with Colorescience to develop products for skin care and protection. Solésence will use patented mineral skin care actives technology to develop sunscreen products exc
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- Congratulations: American Skin Association Announces 2017 Research Scholar Awards and Research Grantshttps://practicaldermatology.com/news/congratulations-american-skin-association-announces-2017-research-scholar-awards-and-research-grants/2458307/And the winners are … The American Skin Association (ASA) research scholar awards and research grants are: ASA Carson Research Sc
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro